G

Genovis AB
STO:GENO

Watchlist Manager
Genovis AB
STO:GENO
Watchlist
Price: 28.05 SEK 3.13% Market Closed
Market Cap: 1.8B SEK
Have any thoughts about
Genovis AB?
Write Note

Genovis AB
Total Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genovis AB
Total Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
G
Genovis AB
STO:GENO
Total Liabilities
kr95.8m
CAGR 3-Years
78%
CAGR 5-Years
47%
CAGR 10-Years
33%
AddLife AB
STO:ALIF B
Total Liabilities
kr7.8B
CAGR 3-Years
51%
CAGR 5-Years
35%
CAGR 10-Years
N/A
BICO Group AB
STO:BICO
Total Liabilities
kr3B
CAGR 3-Years
112%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotage AB
STO:BIOT
Total Liabilities
kr1.1B
CAGR 3-Years
37%
CAGR 5-Years
17%
CAGR 10-Years
24%
MedCap AB (publ)
STO:MCAP
Total Liabilities
kr700.9m
CAGR 3-Years
13%
CAGR 5-Years
9%
CAGR 10-Years
9%
M
Magle Chemoswed Holding AB
STO:MAGLE
Total Liabilities
kr114.7m
CAGR 3-Years
12%
CAGR 5-Years
2%
CAGR 10-Years
N/A
No Stocks Found

Genovis AB
Glance View

Market Cap
1.8B SEK
Industry
Life Sciences Tools & Services

Genovis AB engages in the research and development of enzyme products. The company is headquartered in Lund, Skane. The company went IPO on 2005-11-11. The firm offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The firm markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.

GENO Intrinsic Value
24.64 SEK
Overvaluation 12%
Intrinsic Value
Price
G

See Also

What is Genovis AB's Total Liabilities?
Total Liabilities
95.8m SEK

Based on the financial report for Jun 30, 2024, Genovis AB's Total Liabilities amounts to 95.8m SEK.

What is Genovis AB's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
33%

Over the last year, the Total Liabilities growth was 295%. The average annual Total Liabilities growth rates for Genovis AB have been 78% over the past three years , 47% over the past five years , and 33% over the past ten years .

Back to Top